CRAYON
Every story · every side  ·  est. 1995
Business

CEO turned informant: How the FDA built a case against executives promising cheap medications

CRAYON summary

CNBC reports that the FDA brought a criminal case against an alternative funding program whose executives promised cheap medications. The outlet calls the case unprecedented. Citing a court record, CNBC says the case hinged on the cooperation of a CEO at a peer company who acted as an informant.

Based on CNBC's report - only one outlet has covered this so far. Read the original.
▲ Sign in to vote stories up

Coverage 1 source · 1 report

Chronological.

  1. CNBC FIRST 3h ago CEO turned informant: How the FDA built a case against executives promising cheap medications

    The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.

Discussion 0 comments